Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis

NCT02719171 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02719171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02719171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2016
Completion date
August 31, 2017
Enrollment
185 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic